Jamie Vance
Internal Medicine · Ronceverte, WVNPI 1720349475
Payments from drug & device makers
Across 207 payments — averaging $15.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$699
- Lilly USA, LLC$323
- AbbVie$264
- Amarin Pharma, Inc.$239
- GSK$206
- Biohaven Pharmaceuticals, Inc.$189
- plus $1K from 17 others
What the payments were for
- Food & beverage$3,22399%
- Education$381%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 51 | $699 |
| Lilly USA, LLC | 22 | $323 |
| AbbVie(2 entities) | 15 | $264 |
| Amarin Pharma, Inc. | 14 | $239 |
| GSK | 13 | $206 |
| Biohaven Pharmaceuticals, Inc. | 9 | $189 |
| Amgen | 12 | $186 |
| Pfizer | 10 | $171 |
| AstraZeneca | 11 | $152 |
| E.r. Squibb & Sons, L.L.C. | 8 | $117 |
| Biohaven Pharmaceutical Holding Company Ltd. | 6 | $117 |
| Abbott | 6 | $115 |
| Johnson & Johnson | 7 | $109 |
| Boehringer Ingelheim | 5 | $77 |
| Novartis | 4 | $66 |
| Sunovion Pharmaceuticals Inc. | 3 | $57 |
| Baxter Healthcare | 2 | $36 |
| Dexcom, Inc. | 2 | $31 |
| Esperion Therapeutics, Inc. | 2 | $30 |
| Ultragenyx Pharmaceutical Inc. | 2 | $28 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $18 |
| Nestle Healthcare Nutrition Inc. | 1 | $17 |
| Optinose US, Inc. | 1 | $14 |
How this compares
$3,261 in reported general payments places this provider in the 85th percentile of 573 internal medicine providers in West Virginia.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 28 | $31,895 |
| XareltoRivaroxaban | 21 | $15,571 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 13 | $14,114 |
| Dexlansoprazole DrDexlansoprazole | 16 | $4,407 |
| Sucralfate | 12 | $2,599 |
| SymbicortBudesonide/Formoterol Fumarate | 11 | $2,178 |
| VascepaIcosapent Ethyl | 12 | $2,125 |
| LantusInsulin Glargine,hum.Rec.Anlog | 11 | $1,455 |
| Atorvastatin Calcium | 149 | $1,370 |
| Metoprolol Succinate | 81 | $1,292 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 14 | $1,212 |
| Levothyroxine Sodium | 94 | $1,130 |
| Potassium Chloride | 41 | $1,033 |
| Montelukast Sodium | 100 | $1,015 |
| Famotidine | 79 | $1,013 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $171 | $31,89528 claims |
| Johnson & JohnsonXarelto | $109 | $15,57121 claims |
| GSKTrelegy Ellipta | $206 | $14,11413 claims |
| AstraZenecaSymbicort | $152 | $2,17811 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 573 internal medicine providers in West Virginia.
Other internal medicine in Ronceverte
- Ward PaineMorgantown$5.1M
- William ChapmanCharleston$1.7M
- Mustafa AwiliHuntington$906K
- David PickeringParkersburg$694K
- Laura DavissonMorgantown$118K
- Michael BrumageClendenin$87K
- Govind PatelFairmont$59K
- Lynn SmithLewisburg$31K
- Bisher MustafaHuntington$28K
- Johny AlencherryMartinsburg$27K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.